STI Stock Trade Intelligence
PAB

PATRYS LIMITED

Health Care · ASX:PAB
$0.0230
0.00%
Market cap
$16M
Turnover
$218
Last price
$0.0230
Day change
0.00%
Announcements
17
Range, past year
Open 0.040 · Low 0.001 · Now 0.023 · High 0.052
Open PAB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

PAB momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
25/100
Wyckoff phase
Accumulation4d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+4.5%
1 Month
-14.8%
1 Year
-41.0%
RSI
37
Avg daily range
6.8%

PATRYS LIMITED scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 4 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -40.0%
  • High volatility (ATR 6.8%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
PAB appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

PAB announcements

Recent price-sensitive releases.
  • 2026-10-29 Appendix 4C - Quarterly - 30 September 2026 Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-22 RLS-2202 Phase 1a Trial Advances to Cohort 2 Progress Report
  • 2026-10-13 Investor Presentation Company Presentation
  • 2026-10-06 Investor Webinar Web Cast
  • 2026-09-29 Patrys Completes Cohort 1 Dosing and Follow-Up Progress Report
  • 2026-09-28 Appendix 4E Variance Report Preliminary Final Report
  • 2026-09-23 First Participants Dosed in RLS-2202 Phase 1A Clinical Trial Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.